Clinical Trial Update: A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 open-label study evaluating Alomfilimab (KY1044) alone and with atezolizumab in multiple advanced cancers. The trial was terminated but results have b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer
• Head and Neck Squamous Cell Carcinoma
• Hepatocellular Carcinoma
• Melanoma
• Non-small Cell Lung Cancer
• Pancreatic Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Alomfilimab (KY1044)
• Atezolizumab (atezolizumab)

Snippet

Sponsor: Kymab Limited | Conditions: Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-04-02